<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome has numerous cardiac manifestations, including valvular thickening, insufficiency, and mass lesions </plain></SENT>
<SENT sid="1" pm="."><plain>The mass lesions may be confused with <z:mp ids='MP_0003392'>atrial myxomas</z:mp> and other vegetations, sometimes necessitating a surgical diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>There are no prospective studies on treatment or follow-up of intracardiac lesions in <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>We prospectively followed up three patients with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome for intracardiac lesions (one atrial and two mitral valve masses) complicated by systemic embolization </plain></SENT>
<SENT sid="4" pm="."><plain>Anticoagulation led to complete resolution of the masses in 6 weeks to 3 months </plain></SENT>
<SENT sid="5" pm="."><plain>We propose that initial treatment of an intracardiac lesion in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome should be a trial of systemic anticoagulation before surgical intervention </plain></SENT>
</text></document>